The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
- M Rudwaleit1,
- D van der Heijde2,
- R Landewé3,
- N Akkoc4,
- J Brandt5,
- C T Chou6,
- M Dougados7,
- F Huang8,
- J Gu9,
- Y Kirazli10,
- F Van den Bosch11,
- I Olivieri12,
- E Roussou13,
- S Scarpato14,
- I J Sørensen15,
- R Valle-Oñate16,
- U Weber17,
- J Wei18,
- J Sieper1,19
- 1Department of Medicine, Charité – University Medicine, Berlin, Germany
- 2Leiden University Medical Center, Leiden, The Netherlands
- 3Maastricht University Medical Center, Maastricht, The Netherlands
- 4Dokuz Eylul University Hospital, Izmir, Turkey
- 5Rheumatology Private Practice, Berlin, Germany
- 6Veterans General Hospital, Taipei, Taiwan
- 7Hospital Cochin, Paris, France
- 8Chinese PLA General Hospital, Beijing, China
- 9Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 10University of Ege, Izmir, Turkey
- 11University Hospital, Ghent, Belgium
- 12San Carlo Hospital, Potenza, Italy
- 13King George Hospital, London, UK
- 14M Scarlato Hospital, Scafati, Italy
- 15University Hospital, Copenhagen, Denmark
- 16University Militar Hospital, Bogotá, Colombia
- 17Balgrist University Hospital, Zurich, Switzerland
- 18Chung Shan Medical University, Taichung, Taiwan
- 19German Rheumatology Research Center, Berlin, Germany
- Correspondence to M Rudwaleit, Department of Rheumatology, Ev. Krankenhaus Hagen-Haspe, Brusebrinkstrasse 20, 58135 Hagen, Germany;
- Accepted 3 October 2010
- Published Online First 24 November 2010
Objective To evaluate new classification criteria for peripheral spondyloarthritis (SpA) in patients with SpA with peripheral manifestations only.
Methods In this Assessment of SpondyloArthritis international Society (ASAS) study, two prespecified sets of criteria were compared against the European Spondylarthropathy Study Group (ESSG) and Amor criteria in newly referred consecutive patients with undiagnosed peripheral arthritis, and/or enthesitis, and/or dactylitis that usually began before 45 years of age. The clinical diagnosis (SpA vs no SpA) made by the ASAS rheumatologist served as reference standard.
Results In all, 24 ASAS centres included 266 patients, with a final diagnosis of SpA being made in 66.2%. After adjustments a final set of criteria showed the best balance between sensitivity (77.8%) and specificity (82.9%): arthritis and/or enthesitis and/or dactylitis plus (A) one or more of the following parameters: psoriasis, inflammatory bowel disease, preceding infection, human leucocyte antigen B27, uveitis, sacroiliitis on imaging, or (B) two or more other parameters: arthritis, enthesitis, dactylitis, inflammatory back pain in the past, family history of SpA. The new criteria performed better than modified versions of the ESSG (sensitivity 62.5%, specificity 81.1%) and the Amor criteria (sensitivity 39.8%, specificity 97.8%), particularly regarding sensitivity. In the entire ASAS population of 975 patients the combined use of ASAS criteria for axial SpA and ASAS criteria for peripheral SpA also had a better balance (sensitivity 79.5%, specificity 83.3%) than the modified ESSG (sensitivity 79.1%, specificity 68.8%) and Amor criteria (sensitivity 67.5%, specificity 86.7%), respectively.
Conclusions The new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis.
Participators The following ASAS members who are not authors of this manuscript have contributed by inclusion of at least one patient or have participated in the paper patient exercise: J Braun, Herne, Germany; R Burgos-Vargas, Mexico City, Mexico; E Collantes-Estevez, Cordóba, Spain; J Darmawan, Semarang, Indonesia; J Davis, San Francisco, California, USA; B Dijkmans, Amsterdam, The Netherlands; K de Vlam, Leuven, Belgium; P Emery, Leeds, UK; O Fitzgerald, Dublin, Ireland; R Inman, Toronto, Ontario, Canada; M A Khan, Cleveland, Ohio, USA; M Leirisalo-Repo, Helsinki, Finland; A Linnssen, Ijmuiden, The Netherlands; W Maksymowych, Edmonton, Alberta, Canada; C Naclerio, Scafati, Italy; R Sturrock, Glasgow, UK; I van der Horst-Bruinsma, Amsterdam, The Netherlands; S van der Linden, Maastricht, The Netherlands.
Funding This study was supported financially by ASAS.
Competing interests None.
Ethical approval Ethical approval for the conduct of the study was obtained from local ethical committee in each centre and written informed consent was obtained from all patients.
Provenance and peer review Not commissioned; externally peer reviewed.